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ABSTRACT
Selection of in vitro models that accurately characterize metab-
olite systemic and hepatobiliary exposure remains a challenge
in drug development. In the present study, mechanisms under-
lying differences in systemic exposure of two active metabo-
lites, furamidine and 2,5-bis (5-amidino)-2-pyridyl furan (CPD-
0801), were examined using two hepatic models from rats:
isolated perfused livers (IPLs) and sandwich-cultured hepato-
cytes (SCH). Pafuramidine, a prodrug of furamidine, and 2,5-bis
[5-(N-methoxyamidino)-2-pyridyl] furan (CPD-0868), a prodrug
of CPD-0801, were selected for investigation because CPD-
0801 exhibits greater systemic exposure than furamidine, de-
spite remarkable structural similarity between these two active
metabolites. In both IPLs and SCH, the extent of conversion of
CPD-0868 to CPD-0801 was consistently higher than that of
pafuramidine to furamidine over time (at most 2.5-fold); area
under the curve (AUC) of CPD-0801 in IPL perfusate and SCH
medium was at least 7-fold higher than that of furamidine.
Pharmacokinetic modeling revealed that the rate constant for
basolateral (liver to blood) net efflux (kA_net efflux) of total formed
CPD-0801 (bound  unbound) was 6-fold higher than that of
furamidine. Hepatic accumulation of both active metabolites
was extensive (95% of total formed); the hepatic unbound
fraction (fu,L) of CPD-0801 was 5-fold higher than that of fura-
midine (1.6 versus 0.3%). Incorporation of fu,L into the pharma-
cokinetic model resulted in comparable kA_net efflux,u between
furamidine and CPD-0801. In conclusion, intrahepatic binding
markedly influenced the disposition of these active metabolites.
A higher fu,L explained, in part, the enhanced perfusate AUC of
CPD-0801 compared with furamidine in IPLs. SCH predicted
the disposition of prodrug/metabolite in IPLs.
Introduction
The liver often is the predominant organ for biotransfor-
mation of a precursor compound (i.e., prodrug) to active me-
tabolite, which can influence therapeutic and/or toxicological
outcomes (Pang et al., 2008). Once formed, active metabolite
can undergo further metabolism, excretion into the systemic
circulation or bile, and/or intrahepatic sequestration. There-
fore, accurate characterization of the systemic and hepatobi-
liary exposure of active metabolite is imperative for efficacy
and risk assessment. Although physiologically relevant, in
vivo studies are cumbersome, costly, and associated with a
variety of extrahepatic variables, including metabolic and
active uptake/efflux processes in the intestine and kidney. As
an alternative methodology, in vitro or ex vivo hepatic models
that have strong descriptive and predictive capabilities for
the in vivo situation would offer significant advantages.
Isolated perfused livers (IPLs) are considered the closest
approximation to the hepatobiliary system in vivo because of
maintenance of hepatic architecture, microcirculation, and
bile production (Brouwer and Thurman, 1996). Biotransfor-
mation pathways, sinusoidal/biliary transport processes,
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mechanisms underlying drug-drug interactions, and altera-
tions in physiology (blood flow or changes in protein binding
that might be associated with disease) can be elucidated by
manipulating experimental conditions, in the absence of ex-
trahepatic influences. Despite these advantages, several
shortcomings limit the widespread use of IPLs, such as the
delicate surgical techniques required, the relatively short
experimental period in which viability is maintained (2 h), and
the time/labor-intensive nature of the procedure (Brouwer and
Thurman, 1996).
Sandwich-cultured hepatocytes (SCH) have emerged as an
alternative in vitro model of the hepatobiliary system (Swift
et al., 2010). Unlike conventional culture, hepatocytes cul-
tured between layers of gelled collagen in a sandwich config-
uration establish cell polarity and form intact canalicular
networks with appropriate localization, expression, and func-
tion of transport proteins (LeCluyse et al., 1994; Liu et al.,
1999a). Compared with IPLs, SCH represent a more cost-
effective and high-throughput system, allowing for simulta-
neous monitoring of xenobiotics in both cells and culture
medium over an extended period of time (up to 24 h). One
limitation of SCH is that catalytic activity of cytochrome
P450 enzymes declines with days in culture (Boess et al.,
2003). A medium additive, dexamethasone (DEX), has been
reported to induce the expression of certain phase I and II
enzymes in SCH to levels that more closely approximate in
vivo metabolic activity (LeCluyse, 2001; Hewitt et al.,
2007a,b; Kienhuis et al., 2007).
A large body of literature describes the hepatobiliary dis-
position of many xenobiotics using IPLs or SCH. However, a
comparison of both sinusoidal/canalicular transport and me-
tabolism between these two hepatic models has not been
evaluated. In the current study, two antiparasitic prodrugs
and derived metabolites were used as model drug/metabolite
pairs to investigate this unaddressed issue.
Human African trypanosomiasis (HAT), a neglected para-
sitic disease, consists of two stages. During first-stage infec-
tion, parasites are restricted to the hemolymphatic system;
second-stage infection begins once parasites invade the cen-
tral nervous system, causing serious neurologic dysfunction
(Barrett, 2010). Without treatment, HAT is invariably fatal.
Pafuramidine (Fig. 1), a prodrug of furamidine (Fig. 1), is the
only orally active agent that has shown efficacy in clinical
trials for the treatment of first-stage infection (Paine et al.,
2010). 2,5-Bis [5-(N-methoxyamidino)-2-pyridyl] furan (CPD-
0868) (Fig. 1), a structural analog of pafuramidine and pro-
drug of 2,5-bis (5-amidino)-2-pyridyl furan (CPD-0801) (Fig.
1), demonstrated a higher cure rate compared with pafura-
midine in a second-stage mouse model (4/5 versus 1/5 at 50
mg/kg p.o. for 10 days) (Wenzler et al., 2009); systemic expo-
sure to CPD-0801 was higher than that to furamidine in mice
given the same dose of respective prodrugs (Wu et al.,
2007). These encouraging observations warrant further
evaluation of CPD-0868 as an orally active agent for sec-
ond-stage HAT.
Both furamidine and CPD-0801 are formed in the liver via
sequential oxidative O-demethylation and reductive N-dehy-
droxylation reactions, producing four intermediate phase I
metabolites (Fig. 1) (Zhou et al., 2004; Generaux, 2010). Once
formed, active metabolites must be excreted from hepato-
cytes into the systemic circulation to exert antiparasitic
activity. These observations led to the hypothesis that im-
proved efficacy of the prodrug CPD-0868 against second-
stage infection compared with pafuramidine reflects superior
hepatobiliary disposition characteristics, including a greater
extent of conversion to the active metabolite (CPD-0801)
and/or more efficient efflux of CPD-0801 from hepatocytes
into the systemic circulation. This hypothesis was addressed
using IPLs and SCH from rats, coupled with mathematical
modeling, to elucidate mechanisms underlying the difference
in systemic/hepatobiliary exposure of these two antiparasitic
active metabolites. Results generated from SCH were com-
pared with IPLs.
Fig. 1. Biotransformation of prodrug to active metabolite and corresponding chemical structures.
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Materials and Methods
Materials and Chemicals
Dulbecco’s modified Eagle’s medium (DMEM) and insulin were
purchased from Invitrogen (Carlsbad, CA). ITS (insulin/transfer-
ring/selenium) culture supplement and Matrigel were purchased
from BD Biosciences Discovery Labware (Bedford, MA). Penicillin,
streptomycin, fetal bovine serum, nonessential amino acids (NEAA),
dexamethasone (DEX), Krebs-Henseleit buffer, Triton X-100, and
taurocholate were purchased from Sigma-Aldrich (St. Louis, MO).
The prodrugs pafuramidine and CPD-0868, the intermediate phase I
metabolites (M1, M2, and M3) of pafuramidine, and CPD-0868, the
active metabolites furamidine and CPD-0801, and the internal stan-
dards (deuterium-labeled pafuramidine, CPD-0868, furamidine, and
CPD-0801) were synthesized in the laboratory of Dr. David W. Boy-
kin (Georgia State University, Atlanta, GA) (Boykin et al., 1996;
Ismail et al., 2003; Ismail and Boykin, 2006). All other chemicals
and reagents were of analytical grade and used without further
purification.
Animals
Male Wistar rats (250 –300 g) were purchased from Charles
River Laboratories (Raleigh, NC) for liver perfusion and hepato-
cyte isolation. Animals had free access to water and food before
surgery. All animal procedures were compliant with the guide-
lines of the University of North Carolina Institutional Animal
Care and Use Committee.
Disposition of Prodrugs/Metabolites in Isolated Perfused
Rat Livers
Recirculating IPLs from rats were prepared using standard tech-
niques; perfusions were conducted ex situ over designated times (up
to 2 h) in a temperature-controlled chamber with recirculating oxy-
genated Krebs-Henseleit buffer (80 ml) containing 20% (v/v) rat
blood at a flow rate of 20 ml/min (Brouwer and Thurman, 1996).
Taurocholate was infused (30 mol/h) into the perfusate reservoir to
maintain bile flow. Prodrug (pafuramidine or CPD-0868) stock solu-
tion (80 l; 10 mM in DMSO) was added as a bolus to the perfusate
reservoir to yield an initial concentration of 10 M (0.1% DMSO).
Aliquots of perfusate (400 l) were collected from the IPL reservoir
at 5-min intervals from 0 to 40 min and at 10-min intervals there-
after up to 2 h during perfusion; bile was collected at 10-min inter-
vals; liver was harvested at the end of perfusion. Perfusate plasma,
bile, and liver collections were stored at 80°C pending analysis for
prodrug and derived metabolites by liquid chromatography with
detection by tandem mass spectrometry (LC-MS/MS). The prodrug
concentration (10 M) was based on solubility in perfusate and assay
sensitivity to monitor prodrugs/metabolites in perfusate, liver, and
bile throughout the 2-h experimental period. The absence-of-liver
condition was used to assess nonspecific binding of prodrug and
metabolites to the IPL apparatus.
Determination of Unbound Fraction
Liver. Livers from IPL experiments (described above) were
thawed and homogenized in three volumes (v/w) of 0.1 M phosphate-
buffered saline (PBS). The unbound fraction of formed active metab-
olite in liver homogenates was determined using rapid equilibrium
dialysis devices (Thermo Fisher Scientific, Waltham, MA). Liver
homogenates (200 l) and blank PBS (350 l) were placed in tissue
and buffer chambers, respectively, and incubated (37°C) for 6 h on a
thermomixer (350 rpm) (Eppendorf AG, Hamburg, Germany). Pre-
liminary testing indicated that 6 h of incubation was sufficient to
achieve equilibrium without significant compound degradation. Af-
ter 6 h, aliquots (100 l) were collected from the tissue and buffer
chambers and analyzed for total (bound  unbound) and unbound
formed active metabolite, respectively, by LC-MS/MS.
Perfusate/Plasma. Blank rat IPL perfusate (composed of 20%
rat blood) and plasma were spiked with preformed active metabolite
to yield a total concentration of 1 or 10 M. Spiked perfusate/plasma
(200 l) and blank PBS (350 l) were placed in corresponding dial-
ysis chambers, incubated for 6 h, and analyzed for total (bound 
unbound) and unbound preformed active metabolite, respectively, by
LC-MS/MS.
Disposition of Prodrugs/Metabolites in Sandwich-
Cultured Rat Hepatocytes
Freshly isolated rat hepatocytes were seeded at 1.75  106 cells/
well onto six-well BioCoat collagen plates (BD Biosciences Discovery
Labware) in seeding medium [DMEM containing 5% (v/v) fetal bo-
vine serum, 10 M insulin, 1 M DEX, 2 mM L-glutamine, 1% (v/v)
NEAA, 100 units penicillin G sodium, and 100 g of streptomycin
sulfate]. Approximately 24 h after seeding (day 1), cells were overlaid
with 0.25 mg/ml Matrigel in ice-cold culture medium [DMEM sup-
plemented with 1% (v/v) ITS (insulin/transferrin/selenium), 1 M
DEX, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units penicillin G
sodium, and 100 g/ml streptomycin sulfate]. Thereafter, culture
medium was changed every 24 h for 2 days. On day 4, cells were
incubated with culture medium (1.5 ml) containing pafuramidine or
CPD-0868 at a concentration identical to that used for the IPL
experiments (10 M, 0.1% DMSO). At designated times up to 24 h,
aliquots of medium (500 l) were collected, and cells were washed
twice and incubated at 37°C for 5 min with Hanks’ balanced salt
solution (HBSS) with Ca2 (to maintain bile canalicular networks;
cells  bile) or without Ca2 (to open bile canalicular spaces; cells)
(Lee et al., 2010). After incubation, buffer was removed, and cells
were lysed with ice-cold methanol/water [7:1 (v/v)] containing 0.1%
(v/v) trifluoroacetic acid. Media, cell lysates, and cells  bile lysates
were stored at 80°C pending analysis for prodrug and derived
metabolites by LC-MS/MS. The absence-of-cell condition was used to
assess nonspecific binding of prodrug and metabolites to Matrigel-
overlaid BioCoat collagen plates.
Determination of Hepatocyte Viability
Effect of prodrugs/metabolites on hepatocyte viability was as-
sessed by monitoring lactate dehydrogenase (LDH) release to the
culture medium using a cytotoxicity detection kit (Roche Diagnos-
tics, Indianapolis, IN) according to the manufacturer’s instructions.
In brief, aliquots (25 l) of medium from vehicle-treated (0.1%
DMSO) and prodrug-treated SCH were collected at 0.5, 2, 4, 8, and
24 h. The degree of LDH release was expressed as the percentage of
the maximum cellular LDH release, which was measured by adding
2% detergent, Triton X-100, to SCH (Lee et al., 2008).
LC-MS/MS Analysis for Prodrugs and Derived Metabolites
The concentration of prodrug and derived metabolites in perfus-
ate/plasma or medium, liver homogenates or cell lysates, bile, and
PBS from IPL or SCH studies (described above) was quantified by
LC-MS/MS using a method modified from Wang et al. (2006). In
brief, analytes were extracted by adding methanol/H2O (7:1) with
0.1% trifluoroacetic acid containing 600 nM internal standards, fol-
lowed by vigorous mixing and centrifugation at 1800g for 10 min.
The supernatant (100 l) was transferred to HPLC vials and quan-
tified for prodrug and metabolite using multiple reaction monitoring
via an API 4000 triple quadrupole mass spectrometer (Applied Bio-
systems, Foster City, CA) equipped with a Turbo IonSpray interface
(Applied Biosystems/MDS Sciex, Foster City, CA). Analytes were
separated on an Aquasil C18 HPLC column (2.1 mm  50 mm, 5 m)
(Thermo Fisher Scientific) with a high-pressure linear gradient pro-
gram consisting of 0.1% formic acid in HPLC-grade water (A) and
0.1% formic acid in HPLC-grade methanol (B) delivered by a Shi-
madzu pumping system (Shimadzu, Kyoto, Japan) at a flow rate of
0.75 ml/min as follows: after a 0.5-min initial hold at 10% B, mobile
phase composition was increased from 10 to 90% B over 3.5 min and
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held at 90% B for 0.5 min; the column was re-equilibrated for 0.5 min
before the next injection. For all studies except liver binding, pro-
drugs and metabolites were quantified with calibration standards
(1–10,000 nM) prepared in the appropriate matrix; for the liver
binding study, both active metabolites were quantified with calibra-
tion standards prepared in liver homogenates (0.5–50 M) and PBS
(1–10,000 nM). All calibration curves were linear over the respective
range (R2  0.98). Intraday and interday coefficients of variation
were 15%.
Pharmacokinetic Modeling
Stepwise nonlinear least-squares regression analysis (WinNonlin
5.0.1; Pharsight, Mountain View, CA) was used to fit a compartmen-
tal model (Fig. 2, model 1) to the hepatobiliary disposition of prodrug
and derived metabolites mass versus time data obtained from IPLs
and SCH. Model 2 (Fig. 2) incorporates the unbound fraction of active
metabolite in the liver to emphasize the importance of hepatic bind-
ing in governing the systemic exposure of these compounds. Good-
ness of fit was based on randomness of residuals, correlation matri-
ces, standard errors of parameter estimates, and visual comparison
of predicted mass/concentration-time profiles with observed data.
Because the batch of synthesized pafuramidine standard contained
impurities largely as the intermediate metabolite, M3, an initial
value of 10% of pafuramidine in the dosing compartment (perfusate
for IPLs; medium for SCH) was used to describe M3 disposition in
IPLs and SCH. Some intermediate metabolites (specifically, M1
and M2 of pafuramidine and M2 of CPD-0868) were not included
in the model if concentrations in the perfusate/medium, liver/cells,
and bile were below the limit of quantification (BLQ) or if pure
synthesized standards (M4 of pafuramidine and CPD-0868) were
not available.
Data Analysis
The hepatic clearance (milliliters per minute) and extraction ratio
of prodrug in IPLs were calculated as follows.
Total hepatic clearance (ClH)  dose/AUCperfusate,0-	, where
AUCperfusate,0-	 was calculated as the area under the perfusate con-
centration-time curve from time 0 to infinity using the trapezoidal
method.
Fig. 2. Model schemes depicting disposi-
tion of prodrugs/metabolites in rat IPLs
and SCH (model 1) and hepatic excretion of
unbound active metabolite in rat IPLs
(model 2). kP_net uptake, the first-order rate
constant for net hepatic uptake of prodrug;
kP3M1, the first-order rate constant for
metabolic conversion from prodrug to inter-
mediate metabolite M1; kM1_efflux and
kM1_reuptake, the first-order rate constants
for hepatic basolateral efflux and reuptake
of M1, respectively; kP3M3, the first-order
rate constant for metabolic conversion from
prodrug (pafuramidine only) to intermedi-
ate metabolite M3; kM13M3, the first-order
rate constant for metabolic conversion from
M1 to M3; kM3_efflux, kM3_reuptake, and
kM3_bile, the first-order rate constants for
hepatic basolateral efflux, reuptake, and
biliary excretion of M3, respectively; kM33 A,
the first-order rate constant for metabolic
conversion from M3 to active metabolite;
kA_efflux, kA_reuptake, kA_net efflux, and kA_bile
the first-order rate constants for hepatic
basolateral efflux, reuptake, net basolat-
eral efflux, and biliary excretion of active me-
tabolite, respectively; fu,L, hepatic unbound
fraction of active metabolite; kA_net efflux,u and
kA_bile,u, first-order rate constants for hepatic
basolateral net efflux and biliary excretion of
unbound active metabolite, respectively.
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Biliary clearance (Clb)  massbile,0–120min/AUCperfusate,0–120min,
where massbile,0–120min was calculated as the cumulative amount of
compound excreted into bile over 120 min.
Metabolic clearance (Clm)  ClH  Clb.
Hepatic extraction ratio (EH)  ClH/Q, where Q represents total
perfusate flow rate (20 ml/min). [The blood-to-plasma ratio for both
prodrugs is 1 (unpublished observations).]
With both IPLs and SCH, hepatic accumulation was calculated as
the amount of active metabolite recovered in the liver or cells as a
percentage of the total amount formed over time. Extent of formation
of active metabolite was determined as the total amount of active
metabolite recovered in perfusate, liver, and bile as a percentage of
the initial amount of prodrug added to the perfusate reservoir (IPLs)
or the total amount of active metabolite recovered in medium, cells,
and bile as a percentage of the initial amount of prodrug added to the
culture medium (SCH).
Data showed that distribution of furamidine/CPD-0801 between
liver and perfusate in IPLs, and between cells and medium in SCH,
reached equilibrium from 100 min and 16 h onward, respectively.
Therefore, furamidine/CPD-0801 liver-to-perfusate (IPLs) or cell-to-
medium (SCH) partition coefficients (Kp,IPLs and Kp,SCH, respec-
tively) were calculated as the ratio of concentration in liver (CL) to
that in perfusate (CPer) at the end of the perfusion (120 min) or the
ratio of concentration in cells (CC) to that in medium (CM) at the end
of the incubation (24 h). The hepatocellular volumes used to calculate
CL and CC were 0.6 ml/g rat liver (Pang et al., 1988) and 6.2  10
6
l/hepatocyte (Swift et al., 2010) for IPLs and SCH, respectively.
A two-tailed Student’s t test was used to compare disposition
properties between furamidine and CPD-0801 in IPLs and SCH. A p
value 0.05 was considered statistically significant.
Results
Nonspecific Binding of Prodrugs/Metabolites. Non-
specific binding of both prodrugs and all metabolites to
collagen-coated culture plates, and to the perfusion tubing
and apparatus, was 10% of the initial mass of starting
material. Accordingly, nonspecific binding was assumed to
be negligible.
Disposition of Prodrugs/Metabolites in Isolated Per-
fused Rat Livers. Both prodrugs were taken up and metab-
olized rapidly, as reflected by the prompt appearance of in-
termediate metabolites in perfusate (Fig. 3). Both prodrugs
were eliminated in rat liver primarily by metabolism; biliary
excretion was negligible (Table 1). Pafuramidine had a
higher hepatic extraction ratio than CPD-0868 (Table 1).
Recovery of M1 and M2 metabolites of pafuramidine in per-
fusate, liver, and bile was BLQ. The M3 metabolite of pafura-
midine appeared in the perfusate immediately (Fig. 3A),
reflecting M3 as an impurity in this batch of synthesized
standard of pafuramidine, and then decreased slightly be-
cause of uptake into hepatocytes; at 10 min, M3 began to
increase slightly because of the efflux of M3 formed from M1.
The M1 metabolite of CPD-0868 in perfusate was maximal at
15 min (Fig. 3B), then decreased rapidly, because of re-
uptake into hepatocytes and further metabolism. The M3
metabolite of CPD-0868 in perfusate was maximal at 40
min (Fig. 3B), then decreased because of reuptake into hepa-
tocytes and further metabolism. The rate constants associ-
ated with both basolateral reuptake (kM3_reuptake) and efflux
(kM3_efflux) of the M3 metabolite were comparable between
prodrugs (Table 2). kM3_reuptake was more than 40-fold higher
than kM3_efflux for the M3 metabolite of both prodrugs (Table
2). The rate constant associated with biliary excretion of the
M3 metabolite (kM3_bile) of CPD-0868 was 4-fold higher than
that of the M3 metabolite of pafuramidine (Table 2). The rate
constant associated with conversion from M3 to the active
metabolite (kM33A) of CPD-0868 was 3.5-fold higher than
that of pafuramidine (Table 2).
The extent of formation of furamidine in rat IPLs was at
least half that of CPD-0801 (Fig. 4A). Perfusate exposure to
CPD-0801 was much higher compared with furamidine. The
AUC for CPD-0801 was 10-fold higher than that for furami-
Fig. 3. Disposition of prodrugs pafuramidine (A) and CPD-0868 (B), and
corresponding metabolites over 120 min in rat isolated perfused livers.
Prodrug (10 M) was administered as a bolus to the perfusion reservoir,
which contained 80 ml of 20% (v/v) rat blood. , prodrug; , M1; E, M3;
Œ, active metabolite. Symbols and error bars for perfusate concentrations
denote means and SDs, respectively, of n  5 livers. Symbols and error
bars for liver mass denote means and SDs, respectively, of n  5 livers,
using a destructive sampling strategy. Solid lines represent perfusate
concentration-time profile of prodrug and derived metabolites. Dashed
lines represent liver amount-time profile of active metabolite. Solid and
dashed lines represent the computer-generated best fit of the pharmaco-
kinetic scheme depicted in Fig. 2 (model 1) to the data. Note: pafurami-
dine contained 5 to 10% impurities, largely as M3; M1 from pafuramidine
is not included in A because of low recovery in perfusate, as described
under Results.
TABLE 1







Pafuramidine 17.6 17.6 0.1 0.88
CPD-0868 12.4 12.4 0.1 0.62
Comparison of Metabolite Disposition in Hepatic Models 507
dine (Table 3). Pharmacokinetic modeling (Fig. 2, model 1)
revealed that the rate constant associated with net basolateral
efflux (kA_net efflux) of CPD-0801 was 6-fold higher than that of
furamidine (Table 2).
Hepatic accumulation of both active metabolites in rat
IPLs was extensive (Table 3). The liver-to-perfusate partition
coefficient (Kp,IPLs) of furamidine at 2 h was 3700 and was
approximately 5-fold higher than that of CPD-0801 (Table 3).
The unbound fractions of both active metabolites in plasma/
perfusate were similar at 1 and 10 M. The unbound fraction
of each active metabolite in rat liver (fu,L) was 24-fold lower
than that in plasma (fu,P) and perfusate (composed of 20% rat
blood; fu,Per) (Table 3). The fu,L of CPD-0801 was approxi-
mately 5-fold higher than that of furamidine (Table 3). As-
suming that only unbound drug can translocate out of hepa-
tocytes into blood and bile, fu,L was incorporated into the
pharmacokinetic model (Fig. 2, model 2) to evaluate further
the hepatic excretion of derived active metabolite. Based on
model 2, the rate constant for biliary excretion (kA_bile,u) was
9-fold higher than that of basolateral efflux (kA_net efflux,u) for un-
bound furamidine, whereas kA_bile,u and kA_net efflux,u for CPD-
0801 were more comparable than those for furamidine (Table 4).
After incorporating fu,L, the kA_net efflux,u of furamidine became
comparable with that of CPD-0801 (Table 4).
Disposition of Prodrugs/Metabolites in Day-4 Sand-
wich-Cultured Rat Hepatocytes. The disposition profiles
of prodrugs and derived metabolites in SCH (Fig. 5) were
similar to those for rat IPLs (Fig. 3), although the time course
in SCH was longer than that in IPLs (24 versus 2 h). As
shown in IPLs, the recovery of M1 and M2 metabolites of
pafuramidine in medium, cells, and bile was BLQ; the M3
metabolite of pafuramidine appeared in medium immedi-
ately (Fig. 5A), reflecting M3 as an impurity. The M1 metab-
olite of CPD-0868 in medium was maximal at 2 h (Fig. 5B),
and then decreased rapidly because of subsequent reuptake
into hepatocytes and metabolism. The M3 metabolite of CPD-
0868 in medium was maximal at 8 h (Fig. 5B), then decreased
because of reuptake into hepatocytes and further metabo-
lism. The rate constant associated with conversion from M3
to the active metabolite (kM33A) of CPD-0868 was 1.4-fold
higher than that of pafuramidine (Table 5). Only the M3
metabolite of CPD-0868 was recovered in bile (Table 5).
The extent of conversion of CPD-0868 to CPD-0801 was
consistently higher than that of pafuramidine to furamidine
in SCH over 24 h (Fig. 4B). Medium exposure to CPD-0801
was higher compared with furamidine. The AUC for CPD-
0801 was 7-fold higher than that for furamidine (Table 3). As
shown in IPLs, kA_net efflux of CPD-0801 was 6-fold greater
than that of furamidine. Model 1 adequately described the
disposition of furamidine in medium and hepatocytes (solid
and dashed lines in Fig. 5A); the large variability in the
parameter estimate for kA_net efflux of furamidine may be
caused by the marked difference between the amount of
furamidine recovered in the medium and that recovered in
hepatocytes (two orders of magnitude). Hepatocellular ac-
cumulation of furamidine and CPD-0801 over 24 h was ex-
tensive (Table 3). The cell-to-medium partition coefficients of
both active metabolites measured in SCH (Kp,SCH) was 6- to
7-fold higher than liver-to-perfusate partition coefficients
measured in IPLs (Kp,IPLs); similar to IPL results, Kp,SCH of
furamidine was 5- to 6-fold higher than that of CPD-0801
(Table 3).
Fig. 4. Extent of formation of active metabolites represented as total
amount of active metabolite recovered in perfusate, liver, and bile as a
percentage of the initial amount of prodrug added to the perfusate res-
ervoir from isolated perfused rat liver experiments (A; mean 
 S.D., n 
5 livers) and total amount of active metabolite recovered in medium, cells,
and bile as a percentage of the initial amount of prodrug added to the
culture medium from sandwich-cultured rat hepatocyte experiments
(B; mean 
 S.D., n  2 livers in duplicate). , p  0.05 versus furamidine
(two-tailed Student’s t test).
TABLE 2
Kinetic parameters, generated from model 1, associated with the
disposition of prodrugs (pafuramidine and CPD-0868) and derived
metabolites in rat isolated perfused livers
Kinetic parameters are defined in the legend to Fig. 2. No discernable correlation between
parameters was observed by evaluation of the correlation matrix (absolute correlation value
0.5). See Supplemental Fig. S1 for the plot of weighted residual vs. time data.
Parameter
Pafuramidine/Metabolites CPD-0868 / Metabolites
Estimate CV Estimate CV
h1 % h1 %
kP_net uptake 58 88 13 23
kP3M1 N.A.
b N.A. 3.8 7
kM1_reuptake N.A. N.A. 96 55
kM1_efflux N.A. N.A. 330 62
kP3M3 1.7 6 N.A. N.A.
kM13M3 N.A. N.A. 108 20
kM3_reuptake 13 69 11 33
kM3_efflux 0.31 72 0.20 29
kM3_bile 0.096 11 0.42 14
kM33A 0.43 8 1.5 12
kA_reuptake 2.7 100 3.3 100
kA_efflux 0.0065 100 0.028 100
kA_net efflux
a 0.0021 14 0.012 51
kA_bile 0.020 48 0.0084 61
N.A., not applicable.
a Because of the high variability associated with the parameter estimates for
kA,reuptake and kA_efflux, model 1 was modified to include a net efflux term, kA_net efflux.
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bility. In rat SCH treated with vehicle (0.1% DMSO) or
prodrug (pafuramidine or CPD-0868), an elevation in LDH
release was not observed over 24 h compared with untreated
SCH (data not shown). These data suggested that membrane
integrity remained intact as a function of prodrug treatment
and time.
Discussion
SCH have been used previously to investigate the hepato-
biliary disposition of drug/metabolite pairs, including terfe-
nadine and fexofenadine (Turncliff et al., 2006). The current
work represents the first systematic comparison of two es-
tablished hepatic models, IPLs and SCH, to understand
mechanisms governing the systemic and hepatobiliary expo-
sure of two antiparasitic active metabolites. Rat IPLs and
SCH showed similar disposition profiles of prodrugs and
derived metabolites (Fig. 3 versus Fig. 5). The extent of
formation and AUC in perfusate (IPLs) or medium (SCH) of
CPD-0801 was consistently higher than that of furamidine
(Table 3). A stepwise pharmacokinetic modeling approach
was used to differentiate, quantitatively, between the contri-
bution of hepatic metabolism and transport to the enhanced
perfusate/medium AUC of CPD-0801 compared with furami-
dine. Model 1 described adequately the disposition of both
prodrugs and derived metabolites (Figs. 3 and 5; Supplemen-
tal Figs. S1 and S2) and predicted a net basolateral efflux
rate constant (kA_net efflux) for CPD-0801 that was 6-fold
higher than that for furamidine in both IPLs (Table 2) and
SCH (Table 5). The extent of formation of CPD-0801 was only
2.5-fold higher than that of furamidine (Fig. 4; Table 3).
Fig. 5. Disposition of prodrugs pafuramidine (A) and CPD-0868 (B) and
corresponding metabolites over 24 h in day-4 sandwich-cultured rat hepa-
tocytes. Prodrug (10 M) was administered as a bolus to each well, which
contained 1.5 ml of culture medium. , prodrug; , M1; E, M3; Œ, active
metabolite. Symbols and error bars denote means and SDs, respectively,
of n  2 livers in duplicate. Solid lines represent medium concentration-
time profile of prodrug and derived metabolites. Dashed lines represent
hepatocyte amount-time profile of active metabolite. Solid and dashed
lines represent the computer-generated best fit of the pharmacokinetic
model depicted in Fig. 2 (model 1) to the data. Pafuramidine contained 5
to 10% impurities, primarily M3; M1 from pafuramidine is not included in
A because of low recovery in medium, as described under Results.
TABLE 3
Comparison of hepatic disposition of active metabolites in IPLs and day-4 SCH from rats
Comparisons between furamidine and CPD-0801 for all outcomes were made using the two-tailed Student’s t test (* p  0.05 vs. furamidine). Values denote mean 
 S.D.
Outcome
Rat IPLs Rat SCH
Furamidine CPD-0801 Furamidine CPD-0801
Hepatic accumulation (%) 99 
 1 97 
 1 99 
 0 95 
 1*
Extent of formation (%)a 31 
 6 72 
 14* 49 





 0.002 0.06 
 0.01* 0.6 





3700 800 27,000 4700
fu,L (%)
c 0.3 
 0.1 1.6 
 0.3* N.A. N.A.
fu,Per (%)
d 44 
 5 70 
 6* N.A. N.A.
fu,P (%)
d 24 
 2 38 
 3* N.A. N.A.
N.A., not applicable.
a Measured at the end of the perfusion for IPLs (120 min) and at the end of the incubation for SCH (24 h).
b Calculated as the AUC from 0 to 2 h (IPL) and from 0 to 24 h (SCH), respectively.
c Unbound fraction of formed active metabolite in liver.
d Unbound fraction of preformed active metabolite added to perfusate or plasma at 1 M.
TABLE 4
Kinetic parameters, generated from model 2, associated with the
hepatic excretion of unbound active metabolites in rat isolated perfused
livers
Kinetic parameters are defined in the legend to Fig. 2.
Unbound Active Metabolite
kA_net efflux,u kA_bile,u
Estimate CV Estimate CV
h1 % h1 %
Furamidine 0.66 16 6.0 19
CPD-0801 0.60 42 0.74 40
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These observations indicated that net basolateral efflux pre-
dominated over metabolism in governing perfusate/medium
exposure to active metabolite.
The fu,L of CPD-0801 was 5-fold higher than that of
furamidine. Based on model 2 (Fig. 2), the ratio of biliary
excretion (kA_bile,u) to basolateral efflux (kA_net efflux,u) rate
constants for furamidine was 9 (Table 4), suggesting that
once formed in liver, the predominant process that deter-
mines furamidine elimination is excretion into bile, whereas
biliary and basolateral excretory processes contribute ap-
proximately equally to CPD-0801 hepatic excretion (Table 4).
Incorporation of fu,L in model 2 (Fig. 2) resulted in a compa-
rable kA_net efflux,u of both active metabolites (Table 4),
indicating that the 6-fold difference in the rate constant for
net basolateral efflux of total formed active metabolite
(k
A_net efflux
) could be attributed largely to the 5-fold difference
in hepatic binding.
During an expanded phase I safety study in indigenous
African volunteers, pafuramidine demonstrated transiently
elevated liver transaminanses, a known class effect of diami-
dines (Paine et al., 2010). In rats administered a single oral
dose of pafuramidine (10 mg/kg), liver-to-plasma partitioning
(Kp) of furamidine was as high as 1300 (Midgley et al., 2007).
As shown in the current study, hepatic accumulation of fura-
midine was extensive, and the unbound fraction of furami-
dine in liver was at least 80-fold lower than that in plasma
and perfusate (Table 3). Thus, binding sites in liver may act
as an “intracellular sink” that limit systemic exposure to
furamidine. Previous subcellular fractionation studies dem-
onstrated that furamidine accumulated primarily in the mi-
tochondrial fraction of liver tissue (Midgley et al., 2007).
Consistent with these observations, preliminary fraction-
ation studies with rat IPLs revealed that furamidine was
localized primarily in the mitochondrial fraction (43%); CPD-
0801 was localized primarily in the cytosolic fraction (45%),
with negligible mitochondrial accumulation (1%) (unpub-
lished observations). Extensive accumulation of furamidine
in mitochondria could cause mitochondrial dysfunction and
trigger liver signal elevations (Pessayre et al., 1999). Signif-
icant hepatic accumulation of furamidine is consistent with
previous in vivo data (Midgley et al., 2007), suggesting that
hepatocellular sequestration may limit systemic exposure of
furamidine and predispose the liver to elevated signals. In
contrast, a significantly higher hepatic unbound fraction and
less mitochondrial accumulation of CPD-0801, compared with
furamidine, could enhance systemic exposure to CPD-0801 and
reduce hepatic signals.
Using appropriate preclinical hepatic models to estimate
liver-to-plasma partitioning of potential hepatotoxicants has
been a topic of interest in toxicologic risk assessment. In the
current study, the liver-to-perfusate partition coefficient
(Kp,IPLs) of furamidine measured in IPLs was 3700, approx-
imately 2.8-fold higher than the in vivo Kp (1300) measured
in rats. This discrepancy can be explained by the 2-fold
difference in the extent of protein binding of furamidine in
perfusate (composed of 20% blood) versus plasma (Table 3). If
basolateral membrane barriers are absent, liver-to-plasma
partitioning can be estimated as the ratio of the unbound
fraction of furamidine in plasma to that in liver (i.e., Kp 
fu,P/fu,L  24/0.3  80), assuming the liver is a well stirred
organ (Rowland, 1985). Likewise, Kp,IPLs  fu,Per/fu,L  44/
0.3  147. Both estimated Kp and Kp,IPLs values are much
lower than observed values in IPLs and intact rats, suggest-
ing that active transport may be involved in the increased
hepatic partitioning of furamidine in the intact organ. It is
noteworthy that cell-to-medium partition coefficients of fura-
midine/CPD-0801 measured in SCH (Kp,SCH) overestimated
corresponding values measured in IPLs (Kp,IPLs) by approx-
imately 6-fold. This discrepancy could be explained, in part,
by the absence of serum in culture medium, which resulted in
a higher fu in medium (approximately unity) than that in
perfusate. Therefore, binding differences in transport buffer/
medium and plasma need to be considered when using SCH
to estimate liver-to-plasma partitioning. Nonetheless, both
Kp,SCH and Kp,IPLs of furamidine were 5-fold higher than
those of CPD-0801.
The intermediate metabolite, M3, from both prodrugs was
excreted extensively into bile in IPLs; M3 from CPD-0868
was the most extensively excreted compound in bile among
all prodrugs and metabolites. Both active metabolites also
were recovered in bile, but to a 20- to 50-fold lesser extent
than M3 from CPD-0868 (Table 2). In contrast, only M3 from
CPD-0868 was recovered in bile of SCH. Unlike in IPLs,
biliary excretion in SCH was measured indirectly, by deter-
mining the difference in substrate accumulation between
standard HBSS (cells  bile) and Ca2-free HBSS (cells) (Liu
et al., 1999b). As reported previously, SCH may underpredict
in vivo biliary clearance of compounds because of a less
extensive canalicular network formation relative to whole
liver (Liu et al., 1999b; Hoffmaster et al., 2005; Abe et al.,
2008). To compare the biliary excretion in SCH and IPLs, the
intrinsic biliary clearance of M3 from CPD-0868 in SCH
(Cl
M3_biliary, SCH
) was estimated by multiplying kM3_bile (Table 5)
by the hepatocellular volume of 6.2  106 l/hepatocyte
(Swift et al., 2010), and then scaled up to liters per hour per
gram of liver based on 110  106 hepatocytes/g rat liver (Ito
and Houston, 2004) and 106 hepatocytes/well in six-well
plates. The intrinsic biliary clearance of M3 from CPD-0868 in
IPLs (ClM3_biliary, IPLs) was estimated by multiplying kM3_bile
TABLE 5
Kinetic parameters, generated from model 1, associated with
disposition of prodrugs (pafuramidine and CPD-0868) and derived
metabolites in day-4 rat SCH
Kinetic parameters are defined in the legend to Fig. 2. No discernable correlation
between parameters was observed by evaluation of the correlation matrix (absolute




Estimate CV Estimate CV
h1 % h1 %
kP_net uptake 0.30 7 0.40 4
kP3M1 N.A.
b N.A. 67 37
kM1_reuptake N.A. N.A. 3.5 29
kM1_efflux N.A. N.A. 71 42
kP3M3 1.3 26 N.A. N.A.
kM13M3 N.A. N.A. 12 40
kM3_reuptake 0.080 90 0.15 30
kM3_efflux N.A. N.A. 0.35 27
kM3_bile N.A. N.A. 0.050 55
kM33A 0.46 16 0.66 15
kA_reuptake 0.83 100 0.27 100
kA_efflux 0.0080 100 0.015 100
kA_net efflux
a 0.00076 100 0.0046 27
kA_bile N.A. N.A. N.A. N.A.
N.A., not applicable.
aBecause of the high variability associated with the parameter estimates for
kA,reuptake and kA_efflux, model 1 was modified to include a net efflux term, kA_net efflux.
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(Table 2) by the hepatocellular volume of 0.6 ml/g rat liver
(Pang et al., 1988). Scaled ClM3_biliary, SCH approximated
Cl
M3_biliary, IPLs
(3.4  105 versus 25  105 l/h/g liver) within
an order of magnitude. As shown in rat IPLs, the fraction
of total formed furamidine and CPD-0801 excreted into
bile at 2 h was 3% (calculated by subtraction of the
percentage of hepatic accumulation from unity; Table 3); in
addition, kA_bile of furamidine and CPD-0801 was 20- to
50-fold lower compared with M3 (kM3_bile) from CPD-0868
(Table 2). Therefore, biliary excretion of furamidine/CPD-
0801 may be so small that the difference in substrate
accumulation between standard and Ca2-free HBSS was
indistinguishable.
A previous study showed that CYP4F2 and CYP4F3B
were the major enzymes responsible for pafuramidine O-
demethylation (M1 formation) in human liver microsomes
(Wang et al., 2006). The enzymes involved in this reaction
in rats have not been identified. Cyp1a2, Cyp2d2, and
Cyp4f1 were reported to catalyze CPD-0868 O-demethyla-
tion in rat liver microsomes (Generaux, 2010). In the cur-
rent work, metabolic activity in rat SCH was maintained
by supplementing the culture medium with 1 M DEX, a
standard concentration used in metabolism studies with
SCH (Turncliff et al., 2006). Further studies are warranted
to characterize the effect of DEX concentration on the
expression/activity of the enzymes involved in the bio-
transformation of both prodrugs.
In summary, an integrated approach involving two rat
hepatic systems (IPLs and SCH) and pharmacokinetic mod-
eling provided a mechanistic understanding of the impact of
hepatic binding on the systemic and hepatobiliary exposure
of two antiparasitic active metabolites. As hypothesized, de-
spite structural similarities, CPD-0868 had superior hepato-
biliary disposition characteristics compared with pafurami-
dine, as reflected by more extensive formation of the active
metabolite, CPD-0801, together with higher hepatic basolat-
eral efflux (because of a higher hepatic unbound fraction),
compared with furamidine. The combined effect of both fac-
tors could explain, in part, the enhanced systemic exposure of
CPD-0801. Although the mechanisms of brain penetration
for these active metabolites have not been elucidated, an
increased systemic exposure of CPD-0801 could lead to im-
proved brain exposure. Based on similar in vitro potencies of
both active metabolites against various strains of trypano-
somes (Wenzler et al., 2009), increased brain exposure of
CPD-0801 may enhance antitrypanosomal efficacy in the
central nervous system relative to furamidine. The agree-
ment between results from rat IPLs and SCH further sub-
stantiates SCH as a useful in vitro tool for characterizing
hepatobiliary disposition of xenobiotics. Because human
IPLs are not feasible, human SCH could be used as a surro-
gate to predict hepatobiliary disposition of xenobiotics in
humans.
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